Short-term results of transcatheter aortic valve replacement using Venus A-Plus valve delivery system in patients with severe aortic stenosis: A retrospective cohort study
- VernacularTitle:应用Venus A-Plus瓣膜输送系统行经导管主动脉瓣置换术治疗重度主动脉瓣狭窄的回顾性队列研究
- Author:
Hang ZHANG
1
;
Huajun WANG
1
;
Fengwu SHI
1
;
Su LIU
1
;
Qianli MA
1
;
Jinghui AN
1
Author Information
1. Department of Cardiac Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, P. R. China
- Publication Type:Journal Article
- Keywords:
Severe aortic stenosis;
transcatheter aortic valve replacement;
Venus A-Plus;
bicuspid aortic valve;
Venus A;
valve delivery system;
perivalvular leak;
safety
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(03):438-443
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short-term efficacy of transcatheter aortic valve replacement (TAVR) using Venus A-Plus valve delivery system in patients with severe aortic stenosis. Methods The clinical data of patients undergoing TAVR in our hospital from August 2018 to March 2022 were collected and they were divided into a Venus A-Plus and a Venus A group according to the type of valve delivery system used. The perioperative data of the two groups were compared. Results A total of 121 patients were included, including 70 patients in the Venus A-Plus group [45 males and 25 females with a mean age of (67.81±6.62) years], and 51 patients in the Venus A group [33 males and 18 females with a mean age of (68.25±7.01) years]. All patients underwent TAVR, and the postoperative hemodynamic features (left ventricular ejection fraction, mean cross-valve pressure difference, peak flow rate) were significantly improved (P<0.05). There was no statistical difference in surgical success rate, all-cause mortality, conversion to thorax opening, valve-in-valve placement, moderate or above perivalvular regurgitation, new left bundle branch block or new right bundle branch block between the two groups (P>0.05). Conclusion TAVR with Venus A-Plus valve delivery system in patients with severe aortic stenosis shows comparable efficacy to the first-generation Venus A system and is satisfactory, safe and reliable.
